Bachem AG (Switzerland) and SpheriTech Ltd (UK) collaborate to develop water-based SPPS.
Peptides, crucial for modern medicine, are synthesized using organic solvents, which pose environmental challenges. Bachem is collaborating with UK based SpheriTech to develop water-based solid-phase peptide synthesis (SPPS) to reduce ecological impact.
The ecological challenge of scaling up peptide manufacturing
Peptides are essential for modern medicine as active ingredients for an increasing number of drugs. Today's manufacturing of peptides currently relies on large quantities of organic solvents.
Organic solvents play a crucial role in peptide synthesis, facilitating chemical reactions and ensuring efficient coupling of amino acids. Unfortunately, their use comes at a cost. These solvents can be toxic, flammable, and contribute to greenhouse gas emissions. As the demand for peptide-based drugs grows, finding sustainable alternatives becomes imperative in an industry that must secure the long-term supply of medical ingredients for millions of patients worldwide.
A growing pipeline of clinical projects, including a new generation of medicines against diabetes and obesity, all based on peptides, and combined with tightening environmental regulatory trends, are expected to challenge the current large scale use of solvents approach in the decade to come.
Water-based SPPS - a space to watch for greener and more efficient peptide manufacturing
Bachem has a long track record as a trailblazing innovator, developing and applying new ways to improve peptide manufacturing technology.
That is why Bachem has joined forces with UK-based SpheriTech to investigate a new water-based approach to solid-phase peptide synthesis (SPPS).
Solid-phase peptide synthesis involves assembling amino acids step by step on a solid support. Traditionally, this process occurs in organic solvents. Water-based SPPS, however, replaces these solvents with water as the primary medium.
Working together to bring water-based SPPS out of the research phase
The collaboration aims to reduce the reliance on organic solvents while maintaining high-quality peptide production. By combining SpheriTech's cutting-edge innovation with Bachem's extensive large-scale peptide manufacturing experience, both companies are working together to bring water-based SPPS to a stage where it can be implemented in a commercially viable form. After the successful conclusion of a research phase, SpheriTech will apply the water-based technology to small-scale peptide synthesis, while Bachem will begin to develop the technology for larger scale synthesis.
For more information about SpheriTech visit: https://spheritech.com/
Attachments
Original Link
Permalink
Disclaimer
Bachem Holding AG published this content on
19 August 2024 and is solely responsible for the information contained therein. Distributed by
Public, unedited and unaltered, on
August 19,
2024 at
05:18:07 UTC.
Bachem Holding AG is a Switzerland-based biochemical company that provides services to the pharmaceutical and biotechnology industry. The Company focuses on the process development and manufacturing of peptides and organic molecules as active pharmaceutical ingredients (APIs), as well as on the development of biochemical products for research purposes. Its product portfolio comprises fluorescent dyes for the fluorescence energy transfer (FRET) analysis of receptor-ligand interactions, protein-protein interactions and the cleavage of substrate molecules, as well as glycosylated peptides for the manipulation of drug properties. The Company markets products under the Bachem and Clinalfa brands and operates production facilities in Switzerland and in the United States.
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.